Up to 30% off — ends 7 Aug

ONLY00h00m00s

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Sylvain Garciaz

Institut Paoli-Calmettes

This profile is automatically generated from trusted academic sources.

Google Scholar

How do I reach out?

Meet Kite AI

Contact this professor

Research Interests

Cell Biology

Pharmacology

Cancer Therapy

Cancer Biology

Cytotoxicity

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Collaborators13

Andrew Guirguis

University of Melbourne

Marian Burr

Australian National University

Norbert Vey

Aix-Marseille University

Sharad Kumar

University of South Australia

Wayne Phillips

Adjunct Professor

Monash Health

Georg Ramm

MONASH UNIVERSITY

Olivier Casasnovas

Estelle Duprez

Aix-Marseille University

Tatiana Cañeque

CNRS Délégation Paris B

boris calmels

Institut Paoli-Calmettes

Fiona Brown

MONASH UNIVERSITY

Yoon Lim

University of South Australia

Mark A. Dawson

University of Melbourne

How do I reach out?

Meet Kite AI

Sylvain Garciaz

Assistant Professor

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles20

Venetoclax Resistance in Acute Myeloid Leukemia

Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome

Caspase-2 protects against ferroptotic cell death.

Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML.

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.

[Cancer: The need to believe].

Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.

Long-term survival of <i>NPM1</i> AML treated with intensive chemotherapy with extensive molecular data available.

FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile

Targeting regulated cell death pathways in acute myeloid leukemia

Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death

Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses

Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)

Collaborators13

Andrew Guirguis

Marian Burr

Norbert Vey

Sharad Kumar

Wayne Phillips

Georg Ramm

Olivier Casasnovas

Estelle Duprez

Tatiana Cañeque

boris calmels

Fiona Brown

Yoon Lim

Mark A. Dawson

How do I reach out?